California-based Tempest Therapeutics is laying off 21 of its 26 full-time employees. The cuts come while the biotech is ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, to TPST-1495, the ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and ...

Investing.com -- Shares of Tempest Therapeutics Inc (NASDAQ: TPST) climbed 2.3% premarket today after the company announced it has received Orphan Drug Designation from the U.S. Food and Drug ...

A clinical-stage biotech company developing first-in-class targeted and immune-mediated therapeutics to fight cancer.

This designation follows the company’s previous achievements, including designations received for another of its drugs, amezalpat, for hepatocellular carcinoma. InvestingPro analysis shows the company ...

This designation follows the company’s previous achievements, including designations received for another of its drugs, amezalpat, for hepatocellular carcinoma. InvestingPro analysis shows the ...

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated ...

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated ...